Brief: Lianbio Partner Tarsus Pharmaceuticals Announces U.S. FDA Approval Of Xdemvy
26/07/2023 15:23
July 26 (Reuters) - LianBio LIAN.O :
* LIANBIO PARTNER TARSUS PHARMACEUTICALS ANNOUNCES U.S. FDA
APPROVAL OF XDEMVY™ (LOTILANER OPHTHALMIC SOLUTION) 0.25% FOR
THE TREATMENT OF DEMODEX BLEPHARITIS
* LIANBIO - LIANBIO EXPECTS TO REPORT TOPLINE RESULTS FROM
LIBRA
IN Q4 OF 2023
Source text for Eikon: ID:nGNX5kqFp3
Further company coverage: LIAN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on LianBio
See all newsChina's Zeekr prices US IPO at top of range to raise $441 million (updated)
U.S. STOCKS ON THE MOVE-JetBlue Airways, LPL Financial, Nvidia
U.S. STOCKS ON THE MOVE-Bicycle Therapeutics, Molson Coors, LianBio
LianBio completes strategic review, cuts jobs; shares up
Brief: LianBio Announces Completion Of Strategic Review